Biovica Divitum: For patients with HR+ Metastatic Breast Cancer

Study Information

Study Title

Assessing Thymidine Kinase (TK) levels in HR+ Metastatic Breast Cancer

Study Summary

The purpose of this clinical trial is to evaluate the difference in thymidine kinase levels in patients who are being treated for hormone receptor positive (+) metastatic breast cancer, throughout their regimen.

Disease State

Hormone Receptor Positive (+) Metastatic Breast Cancer

Principal Investigator

Myron Bednar, MD

Phase Observational

If you have any questions regarding this study or think that you or your loved one may be eligible, please contact our Clinical Trial Coordinator by dialing 908.237.1201 extension 262.

Contact HHO

All questions and feedback are welcome, anytime.

    About HHO

    Hunterdon Hematology Oncology is a community oncology group, dedicated to fighting cancer in this community and across the region. Our Doctors, Physician’s Assistants and Nurses work tirelessly. They fight hard so that you can win.


    Sign up for the HHO newsletter to stay up to date on the latest news within the practice and the community.

      © HHO 2022. All rights reserved. Designed by DRAW